{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Aggressive+Behavior&page=3",
    "query": {
      "condition": "Aggressive Behavior",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 468,
    "total_pages": 47,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Aggressive+Behavior&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Aggressive+Behavior&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T09:12:13.083Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00663871",
      "title": "Evaluating the Effects of Omega-3 Fatty Acids on Heart Disease and Behavior",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Mood Disorders",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "Fish Oil",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Soybean Oil (Placebo)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "30 Years to 55 Years"
      },
      "enrollment_count": 272,
      "start_date": "2008-06",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2021-06-11",
      "last_synced_at": "2026-11-05T09:12:13.083Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00663871"
    },
    {
      "nct_id": "NCT02080923",
      "title": "A Brief Intervention to Prevent Adolescent Dating Aggression Perpetration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Offensive Aggression",
        "Sexual Aggression",
        "Dating Violence Perpetration and Victimization"
      ],
      "interventions": [
        {
          "name": "Brief Motivational Interview",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Boston University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "15 Years to 19 Years"
      },
      "enrollment_count": 220,
      "start_date": "2014-04",
      "completion_date": "2017-06-13",
      "has_results": false,
      "last_update_posted_date": "2017-06-21",
      "last_synced_at": "2026-11-05T09:12:13.083Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02080923"
    },
    {
      "nct_id": "NCT00233454",
      "title": "Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Mastocytosis, Aggressive (ASM)",
        "Leukemia, Mast Cell",
        "Hematological Non-mast Cell Lineage Disease (AHNMD)"
      ],
      "interventions": [
        {
          "name": "Midostaurin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jason Robert Gotlib",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2005-03",
      "completion_date": "2011-04-16",
      "has_results": true,
      "last_update_posted_date": "2018-09-20",
      "last_synced_at": "2026-11-05T09:12:13.083Z",
      "location_count": 3,
      "location_summary": "Stanford, California • Boston, Massachusetts • St Louis, Missouri",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00233454"
    },
    {
      "nct_id": "NCT06173518",
      "title": "A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia",
        "Relapsed or Refractory B Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "AUTO1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Autolus Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-11-16",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-05T09:12:13.083Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06173518"
    },
    {
      "nct_id": "NCT03044249",
      "title": "A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psychosis",
        "Dementia",
        "Aggression",
        "Agitation",
        "Alzheimer Dementia"
      ],
      "interventions": [
        {
          "name": "MP-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mediti Pharma Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2017-05-04",
      "completion_date": "2020-01-30",
      "has_results": true,
      "last_update_posted_date": "2021-04-01",
      "last_synced_at": "2026-11-05T09:12:13.083Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Pasadena, California • Fairfield, Connecticut + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03044249"
    },
    {
      "nct_id": "NCT00078949",
      "title": "Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "NCIC Clinical Trials Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 849,
      "start_date": "2003-08-27",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2023-08-23",
      "last_synced_at": "2026-11-05T09:12:13.083Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Hackensack, New Jersey + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00078949"
    },
    {
      "nct_id": "NCT06238648",
      "title": "Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Primary Mediastinal Large B-Cell Lymphoma",
        "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Epcoritamab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Patient Observation",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2024-01-31",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-09-26",
      "last_synced_at": "2026-11-05T09:12:13.083Z",
      "location_count": 6,
      "location_summary": "Rochester, Minnesota • St Louis, Missouri • Hackensack, New Jersey + 3 more",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06238648"
    },
    {
      "nct_id": "NCT06806033",
      "title": "Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma"
      ],
      "interventions": [
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        },
        {
          "name": "Glofitamab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2025-03-05",
      "completion_date": "2029-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-05T09:12:13.083Z",
      "location_count": 33,
      "location_summary": "Anchorage, Alaska • Clovis, California • Fullerton, California + 29 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06806033"
    },
    {
      "nct_id": "NCT00576693",
      "title": "Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "intracranial angioplasty and stenting",
          "type": "DEVICE"
        },
        {
          "name": "intensive medical management",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 451,
      "start_date": "2008-10",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2018-05-30",
      "last_synced_at": "2026-11-05T09:12:13.083Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Glendale, California + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00576693"
    },
    {
      "nct_id": "NCT05583149",
      "title": "Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Refractory Aggressive B-cell Lymphomas",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Aggressive B-cell NHL",
        "Diffuse Large B-cell Lymphoma (DLBCL)",
        "De Novo or Transformed Indolent B-cell Lymphoma",
        "DLBCL, Nos Genetic Subtypes",
        "T Cell/Histiocyte-rich Large B-cell Lymphoma",
        "EBV-Positive DLBCL, Nos",
        "Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL)",
        "High-Grade B-Cell Lymphoma, Nos",
        "C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma",
        "Grade 3b Follicular Lymphoma",
        "C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "ACALABRUTINIB",
          "type": "DRUG"
        },
        {
          "name": "LISOCABTAGENE MARALEUCEL",
          "type": "DRUG"
        },
        {
          "name": "Lymphodepleting chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Patrick C. Johnson, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2023-03-01",
      "completion_date": "2029-03-01",
      "has_results": true,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-11-05T09:12:13.083Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05583149"
    }
  ]
}